Agios to Webcast Conference Call of Third Quarter 2024 Financial Results on October 31, 2024

Rhea-AI Summary

Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and PK activation pioneering therapies for rare diseases, has announced a conference call and live webcast scheduled for Thursday, October 31, 2024, at 8:00 a.m. ET. The purpose of this event is to report the company's third quarter 2024 financial results and business highlights.

Interested parties can access the live webcast of the presentation under the "Events & Presentations" section in the Investors area of Agios' official website at www.agios.com. For those unable to attend the live event, a replay of the webcast will be available on the company's website for a minimum of two weeks following the presentation.

CAMBRIDGE, Mass., Oct. 17, 2024 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and PK activation pioneering therapies for rare diseases, today announced the company will host a conference call and live webcast on Thursday, October 31, 2024, at 8:00 a.m. ET to report its third quarter 2024 financial results and business highlights.

A live webcast of the presentation can be accessed under "Events & Presentations" in the Investors section of the company's website at www.agios.com. A replay of the webcast will be archived on the company’s website for at least two weeks following the presentation.

About Agios
Agios is the pioneering leader in pyruvate kinase (PK) activation and is dedicated to developing and delivering transformative therapies for patients living with rare diseases. In the U.S., Agios markets a first-in-class PK activator for adults with PK deficiency, the first disease-modifying therapy for this rare, lifelong, debilitating hemolytic anemia. Building on the company's deep scientific expertise in classical hematology and leadership in the field of cellular metabolism and rare hematologic diseases, Agios is advancing a robust clinical pipeline of investigational medicines with programs in alpha- and beta-thalassemia, sickle cell disease, pediatric PK deficiency, myelodysplastic syndrome (MDS)-associated anemia and phenylketonuria (PKU). In addition to its clinical pipeline, Agios is advancing a preclinical TMPRSS6 siRNA as a potential treatment for polycythemia vera. For more information, please visit the company’s website at www.agios.com.

Contacts:
Investor Contact
Chris Taylor, VP, Investor Relations and Corporate Communications
Agios Pharmaceuticals
IR@agios.com

Media Contact
Eamonn Nolan, Senior Director, Corporate Communications
Agios Pharmaceuticals
media@agios.com

FAQ

When will Agios Pharmaceuticals (AGIO) report its Q3 2024 financial results?

Agios Pharmaceuticals (AGIO) will report its third quarter 2024 financial results on Thursday, October 31, 2024, at 8:00 a.m. ET during a conference call and live webcast.

How can investors access Agios Pharmaceuticals' (AGIO) Q3 2024 earnings webcast?

Investors can access the live webcast of Agios Pharmaceuticals' (AGIO) Q3 2024 earnings presentation under the "Events & Presentations" section in the Investors area of the company's website at www.agios.com.

Will there be a replay available for Agios Pharmaceuticals' (AGIO) Q3 2024 earnings call?

Yes, a replay of Agios Pharmaceuticals' (AGIO) Q3 2024 earnings webcast will be archived on the company's website for at least two weeks following the presentation.

What will Agios Pharmaceuticals (AGIO) discuss in its October 31, 2024 conference call?

Agios Pharmaceuticals (AGIO) will discuss its third quarter 2024 financial results and provide business highlights during the conference call on October 31, 2024.